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Abstract Background: Despite a 
global decline in mortality and 
morbidity from measles in the last 
decade, outbreaks continue to 
occur in some parts of the world 
including Nigeria. 
Objective: To determine antibody 
response to routine measles vacci-
nation in Nigerian children and 
evaluate vaccine potency.  
Methods:  A prospective study of 
234 children selected from 3 
health centres in an   urban area of 
Lagos, Nigeria. Blood was ob-
tained before and 8-12 weeks af-
ter routine vaccination with Ed-
monston-Zagreb strain of measles 
vaccine. Antibodies were detected 
using the measles antibody neu-
tralization test. Reconstituted vac-
cines samples were analysed for 
potency on monolayers of Vero 
slam cells in 96-well tissue cul-
ture plates. 
Results: Twenty seven(11.5%) had 
pre-vaccination antibodies.  
Seroconversion rate among the 
195 who returned for post-
vaccination sampling was 69.2%: 
It was however 74.2% in children 
with no pre-vaccination antibodies 
compared to 17.6% in those with 
antibodies. (p<0.05). Only six 
(50%) of the measles vaccine vials 
were potent. Seroconversion rate 
among subjects vaccinated from 
potent vials was 74.3% compared 
with 42.9% in those vaccinated 
from non-potent vials (p = 0.006). 
Conclusion: Seroconversion to 
measles vaccination in our envi-
ronment is sub-optimal, partly 
attributable to low vaccine po-
tency. Improvement of vaccine 
handling processes and booster 
doses of the vaccine are recom-
mended. 
 Introduction  
 
The burden of measles, a highly communicable, vaccine 
preventable, disease  is highest in developing countries.1-
2 In 2008, there were over 270,000 reported cases with 
about 197,000 deaths globally, 95% of them in the de-
veloping world.2 Although global measles deaths fell by 
74% between 2000 and 2007 largely due to intensified 
efforts at vaccination,2 there have been continued reports 
of outbreaks in some developing countries, including 
Nigeria.2 Recently, however, there appears to be a resur-
gence in measles outbreaks in developed countries lik  
the United States of America where measles was previ-
ously reported to be practically eradicated.3 This has 
largely been attributed to imported cases of measles as 
well as waning vaccine immunity in previously vacci-
nated children3.  
 
In Nigeria, measles vaccine is routinely administered at 
the age of nine months. Clinically apparent measles be-
fore the 9th month vaccination and in vaccinated chil-
dren,4-5  however suggest  low passive antibody positiv-
ity levels and failure of seroconversion respectively. The 
World Health Organization (WHO) therefore  
recommends a second  dose in childhood either rou-
tinely or through supplementary vaccination activities.1 
Between 2006 and 2007, over 56 million Nigerian chil-
dren aged 9 months to 15 years were vaccinated throug   
massive nationwide measles supplementary immuniza-
tion activities.6  This contributed to the >70% decline in 
global measles mortality during that period.7 In spite of 
this however, outbreaks continue to occur in the coun-
try.2 The Paediatric Association of Nigeria (PAN) as 
part of  it’s commitment to  reducing the burden of vac-
cine preventable diseases in Nigerian children, therefore 
recently recommended a second dose of measles vaccine 
in children.8  Sero-epidemiological studies are essential  
for the  monitoring and evaluation of the effectiveness of 
vaccination programmes. This study is designed to  
assess seroconversion rates after the nine month vacci-
nation among a group of infants and evaluate vaccine 




Materials and methods 
 

































































































   
   
  
  
   
  
  
   
  
   
   
  
   
   
  
   






















































































































































   
  
   
   
  
   


















   
  
   
   
  
   
   
  
   
  
   
   
  
   
   
  
   
  
   






































































































































































































































between children with and those without pre-vaccinatio  
antibodies was found to be statistically significant. p= 
<0.05 (Fisher’s exact test) 
 
Effect of vaccine potency on seroconversion  
 
Twelve vials were analysed for potency. Six (50%) had 
potency levels above the minimum WHO required stan-
dard of log10-3TCID50. (Table 4).  The vaccine potency 
rates were 60%, 25% and 66.7% from centers A, B and 
C respectively. Ninety-four subjects were vaccinated 
from these vials. Forty-three received potent vaccines of 
which 35 returned for the post-vaccination with serocon-
version in 26. Non-potent vaccines were administered to 
51 of which 42 returned for the post-vaccination sam-
pling with seroconversion in 18. The seroconversion 
rates in the two groups were thus 74.3% and 42.9% re-
spectively. xo=7.70, df1= 1, p=0.006.  The duration of 
administration of the vials ranged from 45minutes to 
118minutes but this was found not to be related to the 
vaccine titre. (r=0.23, p=0.48). 
 
Table 4: Potency and duration of administration of measles 






















The WHO recommendation to administer measles at the 
age of nine months is predicated upon the need to main-
tain the delicate balance between the need for early pro-
tection of children and the limitation of possible n u-
tralization of the live vaccine by transplacentally ac-
quired antibodies. Expected seroconversion rate at this 
age under optimal conditions, which   is not always 
achievable is about 85% hence the WHO recommenda-
tion of a second dose of the vaccine  to provide  
immunity in non-responders.1 
The overall seroconversion rate of 69.2% obtained in 
this study is higher than most previous reports from this 
country which range from 24% - 69%.12-14  Higher  rates 
have been reported from similar developing countries 
such as Turkey(77.6%)15 and India (>90%),16   while a 
rate of 68.8% similar to ours was reported from thai-
land17 We also observed variable degrees of seroconver-
sion among study subjects implying variable levels of 













































































































Table 3: Distribution of seroconversion following measles 


















PVA= Pre-vaccination antibodies. All: xo  = 4.70, df2,  
p= 0.095. 
 
Effect of pre-vaccination antibodies on seroconversion 
 
When analysis was restricted to subjects with no  
pre-vaccination antibodies, there was a rise in serocon-
version rates in all the centres while overall rate rose 
from 69.2% to 74.2%. (Table 3).Of the 27 subjects who 
had pre-vaccination antibodies, 17 returned for the post-
vaccination sampling out of which three (17.6%) sero-
converted. Five had a drop in titre, four no longer had 
detectable antibodies while the titre remained the same 





A 4.5 118 
A 4.0 75 
A 4.0 62 
A 2.0 90 
A 1.0 65 
B 3.5 45 
B 2.0 72 
B 2.0 55 
B 1.5 87 
C 3.5 85 
C 3.0 105 
C 1.0 75 
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and April 2007 at three health centres in an urban area of 
Lagos State, Nigeria. One centre(A) was chosen becaus  
it also serves as the Local Government Area(LGA) vac-
cine store from where vaccines are dispensed to the 
other centres. The quality of vaccines there would there-
fore represent the best offered by the LGA. The othrs(B 
and C) were chosen by simple random sampling from a 
list of all the six health centres managed by the LGA. 
Ethical approval was obtained from the research and 
ethics committee of the Lagos University Teaching Hos-
pital (LUTH) and informed consent from parents/
caregivers of study subjects.  Calculated sample size was 
195. An additional 39(20%) subjects were recruited b -





Children aged 9-12 months who were apparently healty 
were consecutively enrolled. Exclusion criteria were 
parent/caretaker refusal, acute illness and a past history 
consistent with measles as defined by the centers for 
disease control.1 Their names, ages, sex, weights, 
lengths as well as telephone numbers and contact ad-
dresses of caregivers were obtained. About 3mls of 
blood was obtained via a peripheral vein from each child 
under aseptic conditions followed by a subcutaneous 
injection of 0.5mls of the Edmonston-Zagreb strain mea-
sles vaccine. The vaccines were both reconstituted and 
administered by National Programme on Immunization 
trained nurses. All were from the same batch and within 
the expiry date of the manufacturer. Subjects were then 
given an 8-week appointment for repeat blood sampling 
as above. Defaulters were contacted through telephone 
calls or home visits and their post- vaccination visits 
rescheduled within a two-week frame. The last doses f 
vaccine in alternate reconstituted vaccine vials were  
transported in an insulated cold box at -40C to the labo-
ratory and stored in a freezer at -800C till time of analy-
sis. The time interval between reconstitution and deliv-
ery of the last dose in each vial was noted. 
 
Laboratory analysis  
 
Measles neutralizing antibodies were detected using the 
measles antibody neutralization test 9-10 which is based 
on the ability of the measles antibodies to measure virus 
infectivity. Serial two-fold dilutions of each serum were 
prepared starting from 1/40 to 1/2560 on 96-well tissue 
culture plates. 0.1ml of measles virus stock in Vero slam 
cells containing 100 TCID50 was then added to each 
serum diluent and incubated at 37oC for an hour.  This 
was further incubated with 0.1ml of Vero slam cells in a 
C02 rich environment for 7 days. Infectivity of the mea-
sles virus on tissue cells was visualised after staining 
with crystal violet. The last column on each plate con-
tained the measles virus stock incubated with Vero slam 
cells alone and served as controls. The end-point of the 
virus titration was taken as the highest dilution with visi-
bly stained cells.  Plates were read by two of the authors 
and there was concordance in the judgments of both 
observers in 421 (98.1%) of 429 readings.  
Seroconversion was defined as either a change from 
negative to positive or a four-fold rise in antibody titre 
following vaccination. Vaccine potency was determined 
according to WHO guidelines on monolayers of Vero 
slam cells in 96-well tissue culture plates.  Serial dilu-
tions of the vaccine were incubated with the cells at 
360C for 7-9 days. Virus end-point titres were calculated 
in CCID50 per vial using the method of Reed and 
Muench.10-11 Analysis was conducted in the virology 
laboratory of the LUTH under the supervision of a vi-




Data was analysed using version 16 of the Statistical 
Programme for Social Sciences (SPSS) and Microsoft 
Excel. Measures of central tendency such as mean and 
standard deviation were generated for continuous vari-
ables like weight and height. Chi-square tests was used 
to test statistical significance between discrete data. 





Pre-vaccination blood samples were obtained from 234 
subjects. Their ages ranged from 8.8 to 12.1 months 
with a mean of 9.5 ± 0.56 months. Mean weight and 
length were 8.5 (±1.0) kg and 73.0(±2.7) cm respec-
tively with 231(99%) having weight for age Z scores 
within two standard deviations of the mean. One hun-
dred and ninety-five returned for the post-vaccination 
sampling resulting in 16.6% attrition rate. Of the rest, 
one died following a diarrhoeal illness, six declined the 
second visit, and five had relocated out of reach while 




The distribution of pre-vaccination antibody titres by 
centre is shown in Table 1.  Thirteen children (5%) had 
neutralizing antibodies at the lowest dilution of 1:40, 
fourteen (5.9%) between 1:80 and 1:2560 while 207
(88.5%) had no detectable antibodies. Following vacci-
nation, 151(77.4%) now had titres at dilutions ranging 
from 1:40 to 1:2560 while 44 (22.6%) had no detectable 
antibodies at a dilution of 1:40. (Table 2) Seroconver-
sion rates are as shown in Table 3.  The overall serocon-
version rate was 69.2% but differed according to centre 
though this did not reach statistical significance.
(p=0.095) 
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with time, 18 children with lower titres may therefore be 
at risk of losing their protective immunity. Seroconver-
sion increases with age at vaccination, corresponding to 
reduced levels of maternal antibodies, the highest rates 
being in children vaccinated after the age of 12months.15  
The role of pre-vaccination antibodies in reducing sero-
conversion as we observed has been previously docu-
mented.13  This underscores the need for a booster dose 
of the vaccine especially in a measles endemic enviro -
ment like ours where early exposure to natural infection 
may have accounted for the presence of pre-vaccination 
antibodies in some subjects.  
 
Though still sub-optimal, the 50% vaccine potency rate 
in this study represents a significant improvement of that 
from previous reports of 11%- 18.2%13-14 in the country. 
This may be a reflection of better vaccine-handling prac-
tices, especially maintenance of the cold-chain advo-
cated for by previous workers.19 This study was however 
conducted in an urban area with relatively more stable 
electricity supply and findings may be differ in rural 
settings where this is not the case. Reconstituted m asles 
vaccines should maintain potency if kept on a foam pad
placed in an  iced pack at 4oC for 24 hours.20 It was 
however obvious during the field study that this tem-
perature was not always maintained. Thus, some chil-
dren vaccinated towards the end of activities may hve 
received vaccines whose potency had deteriorated dur-
ing the process.  
 
Incidentally, the duration of exposure was not directly 
related to vaccine potency implying the role of other 
factors such as potency of the vaccine prior to recnsti-
tution which is a reflection of the quality of storage and 
transportation.  Investigation of these factors was be-
yond the scope of this study but supporting evidence can 
be obtained from the study of  Omilabu 
et al13 who reported that measles vaccines in the Na-
tional Central Cold Store maintained potency while only 
16.7% of them were potent when traced to the points of 
service. It is therefore pertinent for the various agencies 
involved in vaccine handling to address the issues relat-
ing to poor transportation and storage. While immune 
response was mostly directly related to virus titres, an 
important observation was that seroconversion occurred 
in some children who supposedly received low potency 
vaccines. It is possible that they were vaccinated at the 
start of activities or the differences may be based on 
individual immunogenicity but this may constitute room 






The low seroconversion to measles vaccination obtained 
in this study precludes the achievement of a herd immu-
nity of 90% required for measles control. There is thus a 
build-up of susceptibles in the population with contin-
ued risks of outbreaks.1 As global elimination of measles 
will be based on successful elimination in all countries, 
this may continue to compromise present efforts di-
rected at measles control.  Improvement of the mainte-
nance of the cold-chain system of vaccine delivery and a 
second opportunity for measles vaccine are recom-
mended. Seroepidemiological and seroconversion stud-
ies which help to highlight the features of the changing 
epidemiology of the disease are a pre-requisite for ffec-
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